Publications by authors named "Michael Blazing"

Claim this Profile
W
Why Novel Therapies in Preventive Cardiology May Face a Marathon, Not a Sprint.
Joanna S Cavalier, Nishant P Shah, Michael A Blazing

Circulation· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT.
Nishant P Shah, Darren K McGuire, Christopher P Cannon, Robert P Giugliano, Yuliya Lokhnygina, Michael A Blazing

J Am Heart Assoc· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial.
Vishal N Rao, Anand Shah, Jaime McDermott, Stephanie G Barnes, Evan M Murray, Michael A Blazing

Circ Heart Fail· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis.
Eri Toda Kato, David A Morrow, Jianping Guo, David D Berg, Michael A Blazing

Eur Heart J· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT.
Siddharth M Patel, Arman Qamar, Robert P Giugliano, Petr Jarolim, Nicholas A Marston, Michael A Blazing

JAMA Cardiol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.
Nicholas A Marston, Robert P Giugliano, Giorgio E M Melloni, Jeong-Gun Park, Valerie Morrill, Michael A Blazing

JAMA Cardiol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unexplained Dyspnea on Exertion: The Difference the Right Test Can Make.
Vishal N Rao, Michelle D Kelsey, Michael A Blazing, Neha J Pagidipati, Terry A Fortin

Circ Heart Fail· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT.
Christopher B Fordyce, Robert P Giugliano, Christopher P Cannon, Matthew T Roe, Abhinav Sharma, Michael A Blazing

J Am Heart Assoc· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
Kazuma Oyama, Robert P Giugliano, Michael A Blazing, Jeong-Gun Park, Andrew M Tershakovec

J Am Coll Cardiol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials.
Akash Goyal, Tony Schibler, Brooke Alhanti, Karen L Hannan, Christopher B Granger, Michael A Blazing

JAMA Netw Open· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT.
Robert P Giugliano, Baris Gencer, Stephen D Wiviott, Jeong-Gun Park, Charles S Fuchs, Michael A Blazing

JACC CardioOncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations.
Nishant P Shah, Neha J Pajidipati, Robert W McGarrah, Ann Marie Navar, Sreekanth Vemulapalli, Michael A Blazing

Am J Cardiol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response.
Rahul S Loungani, Michael R Rehorn, L Kristin Newby, Jason N Katz, Igor Klem, Michael A Blazing

Am Heart J· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply.
Richard G Bach, Christopher P Cannon, Michael A Blazing

JAMA Cardiol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin.
Michael G Nanna, Ann Marie Navar, Robert P Giugliano, Jennifer A White, Yuliya Lokhnygina, Michael A Blazing

J Am Coll Cardiol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial.
Richard G Bach, Christopher P Cannon, Robert P Giugliano, Jennifer A White, Yuliya Lokhnygina, Michael A Blazing

JAMA Cardiol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial.
Arman Qamar, Robert P Giugliano, Erin A Bohula, Jeong-Gun Park, Petr Jarolim, Michael A Blazing

J Am Coll Cardiol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT).
Abhinav Sharma, Jie-Lena Sun, Yuliya Lokhnygina, Matthew T Roe, Tariq Ahmad, Michael A Blazing

Am J Cardiol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medication Discontinuation in the IMPROVE-IT Trial.
Ann Marie Navar, Matthew T Roe, Jennifer A White, Christopher P Cannon, Yuliya Lokhnygina, Michael A Blazing

Circ Cardiovasc Qual Outcomes· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF.
Marat Fudim, Arun Ganesh, Cindy Green, W Schuyler Jones, Michael A Blazing

Eur Heart J· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial.
Marc P Bonaca, J Antonio Gutierrez, Christopher Cannon, Robert Giugliano, Michael Blazing

Lancet Diabetes Endocrinol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.
Tracey G Simon, Kathleen E Corey, Christopher P Cannon, Michael Blazing, Jeong-Gun Park

Int J Cardiol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status.
Andrew P Ambrosy, Lukasz P Cerbin, Marat Fudim, Robert M Clare, Yuliya Lokhnygina, Michael A Blazing

Am J Cardiol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling survival distribution as a function of time to treatment discontinuation: A dynamic treatment regime approach.
Shu Yang, Anastasios A Tsiatis, Michael Blazing

Biometrics· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Robert P Giugliano, Christopher P Cannon, Michael A Blazing, José C Nicolau, Ramón Corbalán

Circulation· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis